The evolving design and methods for trials evaluating the safety of candidate vaginal microbicides: A systematic review

Sexually Transmitted Diseases

Volumn 40, Issue 9, 2013, Pages 729-736

  Jespers, Vicky ^a   Millwood, Iona Y ^b   Poynten, I Mary ^c   Van Damme, Lut ^d   Kaldor, John M ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; DAPIVIRINE; DOCUSATE SODIUM; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MENFEGOL; METHYLCELLULOSE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; POLYSTYRENE; PRO 2000; TENOFOVIR; TERAMEPROCOL; VIVAGEL;

BLOOD CLOTTING TEST; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COCHRANE LIBRARY; COLPOSCOPY; EMBASE; FEASIBILITY STUDY; GRAM STAINING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER FUNCTION TEST; MEDLINE; PATIENT SAFETY; PELVIC EXAMINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SAMPLE SIZE; STUDY DESIGN; SYSTEMATIC REVIEW; TABLET FORMULATION; TREND STUDY; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA FLORA; VAGINA SMEAR; VAGINAL LAVAGE; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; SEXUALLY TRANSMITTED DISEASES; VAGINA;

EID: 84883281051     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/01.olq.0000431070.38601.03     Document Type: Review

References (30)

1. Arién K, Jespers V, Vanham G. HIV sexual transmission and microbicides. Rev Med Virol 2011. E-pub ahead of print.
2. Poynten IM, Millwood IY, Falster MO, et al. The safety of candidate vaginal microbicides since nonoxynol-9: A systematic review of published studies. AIDS 2009; 23:1245-1254.
3. Thurman AR, Doncel GF. Herpes simplex virus and HIV: Genital infection synergy and novel approaches to dual prevention. Int J STD AIDS 2012; 23:613-619.
4. Mauck C, Rosenberg Z, Van Damme L. Recommendations for the clinical development of topical microbicides: An update. AIDS 2001; 15:857-868.
5. Microbicides Conferences. Available at: Http://www.global-campaign. org/Int-microbicides-Conferences.htm. Accessed January 26; 2013.
6. Global Advocacy for Prevention (AVAC). Available at: Http://data. avac.org/Timeline aspx. Accessed January 26; 2013.
7. Alliance for Microbicide Development database. 2012. Available at: Http://www.microbicide.org/. Accessed December 14; 2012.
8. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369:787-797.
9. CONRAD/WHO. Manual for the standardization of colposcopy for the evaluation of vaginal products. Update 2000.
10. CONRAD/WHO. Manual for the standardization of colposcopy for the evaluation of vaginal products. Update 2004.
11. International Working Group on Vaginal Microbicides. Recommendations for the development of vaginal microbicides. AIDS 1996; 10:1-6.
12. Mauck C, Baker J, Birnkrant D, et al. The use of colposcopy in assessing vaginal irritation in research. AIDS 2000; 14:2221-2227.
13. Guido RS, Cardinal-Busse BJ, McIntyre-Seltman K, et al. Colposcopically obtained images of vulvar, vaginal, and cervical epithelium for assessment of safety of intravaginal agents among normal adolescent females: Comparison with in vivo exam and interobserver agreement. J Low Genit Tract Dis 2003; 7:259-263.
14. Mauck CK, Weiner DH, Lai JJ, et al. Colposcopy: Still useful in microbicide safety trials? Sex Transm Dis 2012; 39:465-469.
15. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: Association with increased acquisition of HIV. AIDS 1998; 12:1699-1706.
16. Nugent R, Krohn M, Hillier S. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29:297-301.
17. Jespers V, Morris G, Nel A, et al. Vaginal microbiota assessment by real time PCR in the Mabgel1 study and the IPM013 Dapivirine ring trial. Microbicides Conference, Sydney, Australia Oral presentation: Abstract 508. 2012.
18. Verhelst R, Verstraelen H, Claeys G, et al. Cloning of 16S rRNA genes amplified from normal and disturbed vaginal microflora suggests a strong association between Atopobium vaginae, Gardnerella vaginalis and bacterial vaginosis. BMC Microbiol 2004; 4:16.
19. Ravel J, Gajer P, Fu L, et al. Twice-daily application of HIV microbicides alter the vaginal microbiota. MBio 2012; 3.
20. Jespers V, Menten J, Smet H, et al. Quantification of bacterial species of the vaginal microbiome in different groups of women, using nucleic acid amplification tests. BMC Microbiol 2012; 12:83.
21. Gumbi PP, Nkwanyana NN, Bere A, et al. Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)Y specific CD8 T-cell responses in the female genital tract during chronic HIV infection. J Virol 2008; 82:8529-8536.
22. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr 2004; 37(suppl 3): S184-S193.
23. Fichorova RN, Lai JJ, Schwartz JL, et al. Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. Cytokine 2011; 55:134-140.
24. Keller MJ, Carpenter CA, Lo Y, et al. Phase I randomized safety study of twice daily dosing of Acidform vaginal gel: Candidate antimicrobial contraceptive. PLoS One 2012; 7:e46901.
25. Rohan LC, Moncla BJ, Kunjara Na Ayudhya RP, et al. In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010; 5:e9310.
26. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database Syst Rev 2012; 11:MR000030.
27. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women. Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, US. Abstract 26LB. 2013.
28. Niedbala RS, Mauck C, Harrison P, et al. Biomarker discovery: Validation and decision-making in product development. Sex Transm Dis 2009; 36(3 suppl):S76-S80.
29. Adverse Event Data NIH Division of AIDS Table for Grading the Severity of Adverse Events. Available at: Http://rsc.tech-res com/Document/ safetyandpharmacovigilance/gradingtables aspx. Accessed January 26, 2013.
30. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74:14-22.